Patent Issued for Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers (USPTO 12084522).

Immatics Biotechnologies GmbH has been granted a patent for peptides and cell-based medicaments that can be used in immunotherapy for urinary bladder cancer and other cancers. The patent explains the different types and stages of bladder cancer, as well as the standard treatments available. The invention focuses on a peptide sequence that can bind to MHC and stimulate T cells that react with the peptide, potentially aiding in the diagnosis and treatment of bladder cancer. The patent also mentions the use of adjuvants and pegylation in the composition of the peptides. This article provides a summary of various topics related to surgery, genetics, oncology, and bladder cancer, presenting research on cystectomy, immunology, lymph nodes, chemotherapy, bone research, immunotherapy, urinary diversion, papillary cancer, drugs and therapies, post-trial research, and risk and prevention. It is a fact-based report that aims to deliver news on research and discoveries from around the world. [Extracted from the article]